Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of ...

Once clinical suspicion has been established for primary biliary cholangitis (PBC), the "serologic hallmark" of the ...

On Tuesday, GSK plc (NYSE:GSK) released the headline results of the GLISTEN global phase 3 trial evaluating linerixibat in ...

Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...

Drugmaker GSK said on Tuesday that its linerixibat candidate had shown "positive" Phase III results in cholestatic pruritus ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase ...

Ipsen presents three late-breaking presentations and eight abstracts across rare cholestatic liver disease portfolio at AASLD 2024Elafibranor was granted marketing authorisation for the treatment of ...

in adults with cholestatic pruritus associated with primary biliary cholangitis, a rare autoimmune liver disease. GLISTEN met its primary endpoint, with linerixibat resulting in an improvement in itch ...

The sNDA was submitted to support full approval of OCA for this indication based on data from the COBALT trial, as well as real-world evidence.

The study enrolled 238 people with primary biliary cholangitis (PBC) and cholestatic pruritus, a medical term for relentless ...